Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.44 |
| ▸ | SGK1 | O00141 | 4/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615225 | 0.90 | PPARG (0.55) | PPARGSLC22A12ITGA1 | |
| SCHEMBL13615118 | 0.88 | BRD4 (0.51) | BRD4PFKFB3FABP4FABP5PPARG | |
| SCHEMBL13615251 | 0.86 | CDK1 (0.52) | BRD4PPARGSLC22A12SGK1MCL1 | |
| SCHEMBL13615141 | 0.85 | SLC22A12 (0.54) | BRD4SLC22A12MCL1 | |
| SCHEMBL13615237 | 0.84 | SLC22A12 (0.47) | PPARGSLC22A12 | |
| SCHEMBL13629290 | 0.82 | BRD4 (0.52) | BRD4PFKFB3FABP4FABP5PPARG | |
| SCHEMBL13615181 | 0.82 | ALDH1A1 (0.56) | SLC22A12HPGDSMN1; SMN2MCL1 | |
| SCHEMBL13615274 | 0.81 | PTGES2 (0.52) | SLC22A12SGK1THRBHPGD | |
| SCHEMBL13615209 | 0.80 | ALDH1A1 (0.50) | SLC22A12THRBHPGDSMN1; SMN2MCL1 | |
| SCHEMBL13615171 | 0.78 | MEN1 (0.48) | SLC22A12THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | BRD4 548/4885PFKFB3 482/4885FABP4 3437/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | BRD4 674/4885PFKFB3 467/4885FABP4 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.